Cadrenal Therapeutics Stock (NASDAQ:CVKD)


Chart

Previous Close

$15.49

52W Range

$5.70 - $22.90

50D Avg

$15.73

200D Avg

$15.13

Market Cap

$28.73M

Avg Vol (3M)

$24.94K

Beta

1.12

Div Yield

-

CVKD Company Profile


Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

4

IPO Date

Jan 20, 2023

Website

CVKD Performance


Peer Comparison


TickerCompany
MLYSMineralys Therapeutics, Inc.
GPCRStructure Therapeutics Inc.
XCURExicure, Inc.
ENOBRenovaro Biosciences Inc.
MNPRMonopar Therapeutics Inc.
CNTACentessa Pharmaceuticals plc